NCT05183737

Effects of Microencapsulated Propolis and Turmeric in Patients With Chronic Kidney Disease

Active, enrolled NA Last updated 3 April 2025

What this trial tests

NA trial testing Microcapsules with turmeric and propolis in Chronic Kidney Diseases in 34 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

7 March 2022

Primary endpoint
1 December 2024

31 December 2026

Quick facts

Lead sponsor	Universidade Federal Fluminense
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	health services research
Enrollment	34
Start date	7 March 2022
Primary completion	1 December 2024
Estimated completion	31 December 2026
Sites	1 location across Brazil

Drugs / interventions tested

• Microcapsules with turmeric and propolis

Conditions studied

• Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
• Inflammation — all drugs for Inflammation →

Sponsor

Universidade Federal Fluminense — full company profile →

Who can join

Adults 18 to 60, any sex, with Chronic Kidney Diseases or Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Oxidative stress and inflammation are correlated with Chronic Kidney Disease (CKD), in a way that they bring several harms to patients, including an increased risk of cardiovascular disease and mortality. Adjuvant therapeutic options such as bioactive compounds present in some foods seem to mitigate inflammation. Turmeric and propolis are foods that have compounds with antioxidant and anti-inflammatory capacity, as they promote the activation of nuclear erythroid transcription factor 2 (Nrf2 - responsible for the synthesis of antioxidant enzymes) and inhibit the activity of nuclear factor Kappa B (NF-κB - which increases the synthesis of inflammatory cytokines). This work aims to evaluate the effects of supplementation of associated propolis and turmeric microcapsules on inflammatory markers in patients with CKD undergoing hemodialysis (HD).

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. The Regulatory Effect of Phytochemicals on Chronic Diseases by Targeting Nrf2-ARE Signaling Pathway.
   He WJ, Lv CH, Chen Z, Shi M, et al · · 2023 · cited 46× · PMID 36829795 · DOI 10.3390/antiox12020236
2. Synbiotics, prebiotics and probiotics for people with chronic kidney disease.
   Cooper TE, Khalid R, Chan S, Craig JC, et al · · 2023 · cited 35× · PMID 37870148 · DOI 10.1002/14651858.cd013631.pub2
3. The Mitochondrion: A Promising Target for Kidney Disease.
   Tanriover C, Copur S, Ucku D, Cakir AB, et al · · 2023 · cited 19× · PMID 36839892 · DOI 10.3390/pharmaceutics15020570
4. Propolis and Their Active Constituents for Chronic Diseases.
   Chavda VP, Chaudhari AZ, Teli D, Balar P, et al · · 2023 · cited 18× · PMID 36830794 · DOI 10.3390/biomedicines11020259
5. Antioxidants for adults with chronic kidney disease.
   Colombijn JM, Hooft L, Jun M, Webster AC, et al · · 2023 · cited 15× · PMID 37916745 · DOI 10.1002/14651858.cd008176.pub3
6. Effects of <i>Curcuma longa</i> L. and Green Propolis Extract-Loaded Microcapsules Supplementation on Inflammation in Hemodialysis Patients: Preliminary Results of a Randomized Clinical Trial.
   Britto I, Couto H, de Paiva BR, de Brito JS, et al · · 2025 · PMID 40566544 · DOI 10.3390/life15060891